Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Focuses On Deals, Pipeline As Post-Revlimid Future Draws Closer

Executive Summary

Celgene's fourth quarter earnings report delivered no revenue surprises, but the company noted its pipeline progress and insisted that business development is the main priority for its $12bn in cash as it looks to bring in new assets that can boost post-Revlimid growth.


Related Content

ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends
What Was On Hold Is New Again As Impact Raises $22.5m For Fedratinib
Celgene Eyes IO Growth With BeiGene China Pact
Celgene Joins Evotec In Its First Neurodegenerative Drug Discovery Effort
Celgene diversifies with $7.2bn Receptos buy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts